Clinical and self-reported markers of reproductive function in female survivors of childhood Hodgkin lymphoma.
Anti-Mullerian hormone
Childhood Hodgkin lymphoma
Ovarian reserve
Pregnancy
Reproductive ability
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
22
05
2023
accepted:
28
06
2023
pubmed:
31
7
2023
medline:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
To evaluate the impact of treatment for Hodgkin lymphoma (HL) on clinical reproductive markers and pregnancy outcomes. This study was embedded within the DCOG LATER-VEVO study; a Dutch, multicenter, retrospective cohort study between 2004 and 2014. Serum anti-Müllerian hormone (AMH), follicle stimulating hormone (FSH), inhibin B, antral follicle count (AFC), and self-reported (first) pregnancy outcomes were evaluated in female childhood HL survivors and controls. 84 HL survivors and 798 controls were included, aged 29.6 and 32.7 years old at time of assessment. Median age at HL diagnosis was 13.4 years. Cyclophosphamide equivalent dose (CED-score) exceeded 6000 mg/m HL survivors appear to have an impaired ovarian reserve. However, chance to achieve pregnancy seems reassuring at a young age. Additional follow-up studies are needed to assess fertile life span and reproductive potential of HL survivors, in particular for current HL treatments that are hypothesized to be less gonadotoxic.
Identifiants
pubmed: 37522923
doi: 10.1007/s00432-023-05035-z
pii: 10.1007/s00432-023-05035-z
pmc: PMC10590326
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13677-13695Informations de copyright
© 2023. The Author(s).
Références
Fertil Steril. 2022 Feb;117(2):387-395
pubmed: 34933761
J Natl Cancer Inst. 2017 Nov 1;109(11):
pubmed: 28419299
BMC Pediatr. 2011 Feb 25;11:20
pubmed: 21352536
Lancet Oncol. 2022 Jan;23(1):125-137
pubmed: 34895479
Hum Reprod. 2008 Jan;23(1):178-86
pubmed: 18024486
J Assist Reprod Genet. 2019 Feb;36(2):341-348
pubmed: 30362055
J Clin Endocrinol Metab. 2007 Oct;92(10):3869-74
pubmed: 17726078
Fertil Steril. 2012 Nov;98(5):1097-102
pubmed: 22921077
Lancet Oncol. 2013 Aug;14(9):873-81
pubmed: 23856401
Front Endocrinol (Lausanne). 2021 Mar 18;12:601752
pubmed: 33815272
J Chemother. 1995 Oct;7(5):463-6
pubmed: 8596134
J Cancer Res Clin Oncol. 2020 Jun;146(6):1451-1462
pubmed: 32221745
Hum Reprod. 2018 Aug 1;33(8):1474-1488
pubmed: 29982673
Semin Oncol. 1982 Mar;9(1):84-94
pubmed: 6176028
Pediatr Blood Cancer. 2018 Sep;65(9):e27232
pubmed: 29750388
J Clin Oncol. 2009 Jun 1;27(16):2677-85
pubmed: 19364965
J Clin Oncol. 1996 May;14(5):1718-29
pubmed: 8622093
Hum Reprod. 2008 Nov;23(11):2506-12
pubmed: 18664468
J Clin Oncol. 2018 Jul 20;36(21):2216-2222
pubmed: 29874139
BMC Cancer. 2012 Aug 23;12:363
pubmed: 22917040
Am J Obstet Gynecol. 2017 Dec;217(6):667.e1-667.e8
pubmed: 28917614
Hum Reprod. 2016 May;31(5):926-37
pubmed: 27008889
Hum Reprod Update. 2002 Mar-Apr;8(2):141-54
pubmed: 12099629
Pediatr Blood Cancer. 2014 Jan;61(1):53-67
pubmed: 23940101
J Cancer Surviv. 2014 Dec;8(4):548-54
pubmed: 24810980
Lancet. 2010 Sep 11;376(9744):911-21
pubmed: 20708256
Hum Reprod. 2018 Jul 1;33(7):1281-1290
pubmed: 29912328
Int J Cancer. 2010 Oct 1;127(7):1669-79
pubmed: 20054856
Med Pediatr Oncol. 1999 May;32(5):366-72
pubmed: 10219339
Hum Reprod Update. 2022 May 2;28(3):417-434
pubmed: 35199161
Nat Rev Clin Oncol. 2012 Jun 12;9(8):450-9
pubmed: 22688578
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):867-73
pubmed: 19632060
Nat Rev Cancer. 2014 Jan;14(1):61-70
pubmed: 24304873
J Clin Oncol. 2010 Aug 10;28(23):3680-6
pubmed: 20625128
JAMA. 2017 Oct 10;318(14):1367-1376
pubmed: 29049585
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2239-47
pubmed: 19661083
Br J Cancer. 1996 Jul;74(2):291-6
pubmed: 8688339
Pediatr Blood Cancer. 2021 Apr;68(4):e28894
pubmed: 33459500
J Clin Oncol. 2017 May 10;35(14):1577-1583
pubmed: 28350518
N Engl J Med. 1981 Jun 4;304(23):1377-82
pubmed: 7231460
Gynecol Endocrinol. 2017 Aug;33(8):644-648
pubmed: 28393651
BMJ. 2003 Aug 23;327(7412):434-6
pubmed: 12933733
Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):873-80
pubmed: 2211255
Pediatr Hematol Oncol. 1988;5(4):269-77
pubmed: 3152972
Hum Reprod. 2003 Sep;18(9):1959-66
pubmed: 12923157
Oncologist. 2018 Feb;23(2):214-224
pubmed: 29158370
J Clin Oncol. 2012 Nov 1;30(31):3854-63
pubmed: 23008303
Ups J Med Sci. 2020 May;125(2):112-120
pubmed: 32356507
Fertil Steril. 2003 Mar;79(3):577-84
pubmed: 12620443
Cancer. 1980 Nov 15;46(10):2123-5
pubmed: 7427856
Int J Endocrinol. 2013;2013:125080
pubmed: 24396344
Lancet Oncol. 2021 Feb;22(2):e45-e56
pubmed: 33539753
Med Pediatr Oncol. 1996 Aug;27(2):74-8
pubmed: 8649323
Early Hum Dev. 2009 Dec;85(12):737-44
pubmed: 19914013
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Endocr Rev. 2009 Aug;30(5):465-93
pubmed: 19589949
ISRN Obstet Gynecol. 2012;2012:807302
pubmed: 22462006
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1461-4
pubmed: 7635789
Lancet Oncol. 2016 May;17(5):567-76
pubmed: 27020005
Cancer. 2021 Oct 15;127(20):3881-3892
pubmed: 34297360
Hum Reprod. 2017 Jan;32(1):193-200
pubmed: 27821706
PLoS One. 2011;6(7):e22024
pubmed: 21789206
Cancer. 2010 Oct 15;116(20):4866-71
pubmed: 20629028
Lancet Oncol. 2015 Jun;16(6):667-75
pubmed: 25959806
Reprod Biomed Online. 2014 Sep;29(3):352-61
pubmed: 25047538
Am J Obstet Gynecol. 2002 Oct;187(4):1070-80
pubmed: 12389007
Hum Reprod. 2021 May 17;36(6):1561-1573
pubmed: 33744927
Am J Epidemiol. 1998 Dec 15;148(12):1195-205
pubmed: 9867266
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32270202
Front Endocrinol (Lausanne). 2020 Oct 07;11:574263
pubmed: 33117288
Int J Cancer. 2008 Dec 15;123(12):2891-8
pubmed: 18798259
Hum Reprod Update. 2023 Jul 5;29(4):486-517
pubmed: 36779325
Hum Reprod Update. 2014 Sep-Oct;20(5):688-701
pubmed: 24821925
Fertil Steril. 2019 Feb;111(2):372-380
pubmed: 30691634